Allergic bronchopulmonary Aspergillosis in children.
Allergic bronchopulmonary aspergillosis
asthma
child
cystic fibrosis
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
19
04
2021
accepted:
27
11
2021
pubmed:
28
6
2021
medline:
1
12
2022
entrez:
27
6
2021
Statut:
ppublish
Résumé
Allergic bronchopulmonary aspergillus (ABPA) is a lung disease caused by hypersensitivity from Aspergillus fumigatus. Diagnostic criteria, staging systems and treatment methods for ABPA disease have been reported in studies evaluating populations, the majority of which are adult patients. Our study aimed to discuss the use of ABPA diagnostic criteria in children, the success of other alternative regimens to oral corticosteroids in the treatment of ABPA, and the changes that occur during treatment, in the light of the literature. Between January 2017 and 2020, patients diagnosed with ABPA at the Dokuz Eylül University Child Allergy and Immunology clinic were identified; demographic characteristics, clinical and laboratory findings, diagnostic scores and stages, and treatment protocols were analyzed retrospectively. The mean age of patients diagnosed with ABPA was 14.33 ± 1.96. At the time of ABPA diagnosis, the median total IgE level was 1033 IU/mL (1004-6129), and the median AF specific IgE was 10.64 (2.59-49.70) kU/L. Bronchiectasis was detected in HRCT of 5 cases. We detected significant improvement in spirometric analysis with omalizumab treatment in our patient with steroid-related complications. Today, although risk factors have been investigated for ABPA, it has not been revealed clearly. Both diagnostic criteria and treatment regimens have been described in research studies, mostly adults. In pediatric patients; clarification of diagnosis and treatment algorithms is necessary to prevent irreversible lung tissue damage and possible drug side effects.
Sections du résumé
BACKGROUND
BACKGROUND
Allergic bronchopulmonary aspergillus (ABPA) is a lung disease caused by hypersensitivity from Aspergillus fumigatus. Diagnostic criteria, staging systems and treatment methods for ABPA disease have been reported in studies evaluating populations, the majority of which are adult patients. Our study aimed to discuss the use of ABPA diagnostic criteria in children, the success of other alternative regimens to oral corticosteroids in the treatment of ABPA, and the changes that occur during treatment, in the light of the literature.
METHODS
METHODS
Between January 2017 and 2020, patients diagnosed with ABPA at the Dokuz Eylül University Child Allergy and Immunology clinic were identified; demographic characteristics, clinical and laboratory findings, diagnostic scores and stages, and treatment protocols were analyzed retrospectively.
RESULTS
RESULTS
The mean age of patients diagnosed with ABPA was 14.33 ± 1.96. At the time of ABPA diagnosis, the median total IgE level was 1033 IU/mL (1004-6129), and the median AF specific IgE was 10.64 (2.59-49.70) kU/L. Bronchiectasis was detected in HRCT of 5 cases. We detected significant improvement in spirometric analysis with omalizumab treatment in our patient with steroid-related complications.
DISCUSSION
CONCLUSIONS
Today, although risk factors have been investigated for ABPA, it has not been revealed clearly. Both diagnostic criteria and treatment regimens have been described in research studies, mostly adults. In pediatric patients; clarification of diagnosis and treatment algorithms is necessary to prevent irreversible lung tissue damage and possible drug side effects.
Identifiants
pubmed: 34174797
doi: 10.3906/sag-2104-227
pmc: PMC8742489
doi:
Substances chimiques
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2554-2563Références
Allergy. 2005 Aug;60(8):1004-13
pubmed: 15969680
Thorax. 1952 Dec;7(4):317-33
pubmed: 13015523
Mycoses. 2019 Sep;62(9):761-764
pubmed: 31152616
Clin Exp Allergy. 2015 Dec;45(12):1765-78
pubmed: 26177981
J Pediatr. 1998 Apr;132(4):589-95
pubmed: 9580754
Pediatr Pulmonol. 2014 May;49(5):503-7
pubmed: 24167019
Allergy Asthma Proc. 2015 Nov-Dec;36(6):493-500
pubmed: 26534756
Clin Exp Allergy. 2013 Aug;43(8):850-73
pubmed: 23889240
Ann Intern Med. 1977 Apr;86(4):405-14
pubmed: 848802
Pediatr Pulmonol. 2017 Feb;52(2):190-197
pubmed: 27717223
J Cyst Fibros. 2009 Jul;8(4):253-7
pubmed: 19447081
Lung India. 2018 Nov-Dec;35(6):499-507
pubmed: 30381560
Eur J Pediatr. 2005 Sep;164(9):577-82
pubmed: 15926067
J Allergy Clin Immunol. 2002 Nov;110(5):685-92
pubmed: 12417875
Chest. 2006 Aug;130(2):442-8
pubmed: 16899843
Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S225-64
pubmed: 12975753
Expert Rev Respir Med. 2016 Dec;10(12):1317-1334
pubmed: 27744712
Eur Respir J. 2006 Mar;27(3):615-26
pubmed: 16507864
Lung India. 2015 Apr;32(Suppl 1):S3-S42
pubmed: 25948889
Mycoses. 2014 Nov;57(11):659-63
pubmed: 24963741
Br J Clin Pharmacol. 2001 May;51(5):443-50
pubmed: 11422002
Expert Rev Respir Med. 2012 Aug;6(4):363-71
pubmed: 22971061
Clin Mol Allergy. 2009 Mar 12;7:5
pubmed: 19284628